**Summary of Tristel PLCs Half-Year Financial Report (H1 FY26):**
Tristel PLC, a manufacturer of infection prevention products, reported strong unaudited interim results for the six months ended 31 December 2025, highlighting revenue growth and improved profitability. Key financial and operational highlights include
### **Financial Highlights**
**Revenue Growth** Revenue increased by 14% to £25.65 million (H1 FY25: £22.57 million), driven by strong performance across core markets.
**UK and Overseas Sales** UK sales rose 13% to £9.88 million, while overseas sales grew 14% to £15.77 million, with a sixfold increase in the USA.
**Gross Margin** Remained stable at 81% (H1 FY25: 82%).
**Profitability** Reported EBITDA rose to £6.83 million (H1 FY25: £5.02 million), with adjusted EBITDA up 17% to £7.34 million. Reported profit before tax increased 36% to £4.96 million, and adjusted profit before tax grew 11% to £5.47 million.
**EPS** Basic reported EPS increased 45% to 8.28p, and adjusted EPS rose to 9.36p.
**Cash Position** The company remains debt-free with cash and short-term investments of £13.29 million (H1 FY25: £11.74 million).
**Dividend** Interim dividend maintained at 5.68p per share.
### **Operational Highlights**
**Product Launches** Introduced Tristel OPH in the US for ophthalmic devices and VISICLEANâ„¢ for improved cleaning efficiency.
**Regulatory Developments** Updated AIUM guidelines now include chlorine dioxide for ultrasound probe disinfection, enhancing adoption of Tristel ULTâ„¢ in the US.
**Manufacturing** Successfully transitioned to in-house wipe manufacture, expected to reduce unit costs in H2.
**Leadership** Appointed Anna Wasyl as CFO
CEO Matt Sassone announced his departure at the end of FY26.
### **Regional Performance**
**Americas** Revenue surged 236% year-on-year, with US sales increasing 542% due to strong ULT product sales and clinical validation.
**UK and EMEA** Double-digit growth in key markets like the Netherlands, France, Germany, and Italy.
**APAC** Mixed performance, with modest growth in Australasia and a 2% decline in the rest of the region.
### **Growth Initiatives**
Continued investment in commercial infrastructure, digital capabilities, and innovation pipeline.
Focus on clinical evidence generation and KOL engagement to support market adoption.
### **Outlook**
Tristel remains on track to meet market expectations for FY26, with international expansion, particularly in the US, driving growth. The company is well-positioned for long-term value creation despite the CEO transition.
**Conclusion**
Tristel PLC delivered robust H1 FY26 results, underpinned by strong revenue growth, improved profitability, and strategic advancements in key markets. The company’s debt-free position, progressive dividend policy, and focus on innovation reinforce its growth trajectory.